ReviewCNS neuroscience & therapeutics2026
Double-Duty Drugs: Repositioning Antipsychotics to Combat Bacterial Infections.
Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Double-Duty Drugs: Repositioning Antipsychotics to Combat Bacterial Infections.CNS neuroscience & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis article provides a comprehensive review of the antibacterial properties of antipsychotics, exploring proposed pathways and mechanisms of action. While experimental evidence supports certain mechanisms, such as efflux pump inhibition, others, including the impact on the respiratory chain in M. tuberculosis and cell wall inhibition, remain insufficiently substantiated.
methodsCurrent research primarily relies on in vitro experiments, with limited exploration of in vivo effects. The influence of antipsychotics on gut microbiota poses a significant concern, as alterations may lead to dysbiosis, which has been linked to various illnesses. Additionally, antimicrobial drugs can exert selective pressure, fostering resistance in bacterial strains.
resultsRepositioning antipsychotics as antimicrobials is further complicated by the need for higher doses than those approved for therapeutic use in humans, raising safety concerns. The use of antipsychotics in non-psychotic populations is particularly problematic due to a lack of proven efficacy and potential adverse effects, such as metabolic disturbances, movement disorders, and sleep issues.
conclusionsThese challenges highlight the need for extensive in vivo and clinical studies to evaluate the antibacterial potential of antipsychotics, ensuring safety and efficacy. Careful monitoring and a balanced risk-benefit analysis are essential when considering antipsychotics for antimicrobial purposes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.